Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGB | P11216 | 8/20 | 0.43 |
| ▸ | PYGL | P06737 | 3/20 | 0.41 |
| ▸ | PYGM | P11217 | 2/20 | 0.41 |
| ▸ | OGA | O60502 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | GBA1 | P04062 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8216944 | 1.00 | PYGB (0.43) | PYGBPYGLPYGMOGALMNA | |
| SCHEMBL29732640 | 1.00 | PYGB (0.43) | PYGBPYGLPYGMOGALMNA | |
| SCHEMBL9296731 | 1.00 | PYGB (0.43) | PYGBPYGLPYGMOGALMNA | |
| SCHEMBL8510122 | 1.00 | PYGB (0.43) | PYGBPYGLPYGMOGALMNA | |
| SCHEMBL8201558 | 0.81 | PYGB (0.40) | PYGBPYGLPYGM | |
| Acetic Acid SCHEMBL30370283 | 0.81 | PYGB (0.42) | PYGBPYGLPYGMOGALMNA | |
| SCHEMBL30913907 | 0.78 | MEN1 (0.54) | — | |
| SCHEMBL30906670 | 0.76 | PYGB (0.44) | PYGBPYGLPYGMOGALMNA | |
| SCHEMBL30536487 | 0.76 | PYGB (0.44) | PYGBPYGLPYGMOGALMNA | |
| SCHEMBL3432011 | 0.76 | PYGB (0.44) | PYGBPYGLPYGMOGALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220098228-A1 | METHODS AND COMPOSITIONS FOR IMPROVING THE IMMUNE SYSTEM AND PROVIDING IMMUNO-PROTECTION | NATREON, INC. (US) | 2022-03-31 | — | — | US | claimed |
| WO-2022067196-A1 | METHODS AND COMPOSITIONS FOR IMPROVING THE IMMUNE SYSTEM AND PROVIDING IMMUNO-PROTECTION | NATREON, INC. (US) | 2022-03-31 | — | — | WO | claimed |
| WO-2022067196-A1 | METHODS AND COMPOSITIONS FOR IMPROVING THE IMMUNE SYSTEM AND PROVIDING IMMUNO-PROTECTION | NATREON, INC. (US) | 2022-03-31 | — | — | WO | disclosed |
| US-20220098228-A1 | METHODS AND COMPOSITIONS FOR IMPROVING THE IMMUNE SYSTEM AND PROVIDING IMMUNO-PROTECTION | NATREON, INC. (US) | 2022-03-31 | — | — | US | disclosed |
| EP-3390382-A1 | SUBSTITUTED 4-PHENYL PYRIDINE COMPOUNDS AS NON-SYSTEMIC TGR5 AGONISTS | Ardelyx, Inc. (US) | 2018-10-24 | — | — | EP | disclosed |
| WO-2017106818-A1 | SUBSTITUTED 4-PHENYL PYRIDINE COMPOUNDS AS NON-SYSTEMIC TGR5 AGONISTS | ARDELYX, INC. (US) | 2017-06-22 | — | — | WO | disclosed |
| CN-104082294-A | Method for using 3-aryl-5-methyl butyrate compound as anti-plant virus agent | UNIV HEBEI TECHNOLOGY | 2014-10-08 | — | — | CN | disclosed |
| CN-104082294-A | Method for using 3-aryl-5-methyl butyrate compound as anti-plant virus agent | UNIV HEBEI TECHNOLOGY | 2014-10-08 | — | — | CN | disclosed |
| CN-103467463-A | Lignin derivatives as well as preparation method and use thereof | UNIV NANKAI | 2013-12-25 | — | — | CN | disclosed |
| CN-103193769-A | 4-methyl-1,2,3-thiadiazole-5-triazole compound as well as preparation method and use thereof | UNIV NANKAI | 2013-07-10 | — | — | CN | disclosed |
| CN-101157711-B | Compound having antineoplastic activity and uses thereof | UNIV XIAN JIAOTONG | 2010-12-08 | — | — | CN | disclosed |
| WO-2010018438-A2 | TETRAZOLE GLYCOSIDES | HETERO RESEARCH FOUNDATION (IN) | 2010-02-18 | — | — | WO | disclosed |
| CN-100579973-C | Process for producing glucal | CHENGDU INST BIOLOGY CAS | 2010-01-13 | — | — | CN | disclosed |
| CN-101245057-A | Process for producing glucal | CHENGDU RES INST OF BIOLOGY CH (CN) | 2008-08-20 | — | — | CN | disclosed |
| CN-101157711-A | Compound having antineoplastic activity and uses thereof | UNIV XI AN JIAOTONG (CN) | 2008-04-09 | — | — | CN | disclosed |
| US-6878690-B2 | Compounds and methods | PHARMAXIS PTY LTD. (AU) | 2005-04-12 | — | — | US | disclosed |
| EP-1301522-A4 | NOVEL COMPOUNDS AND METHODS | PHARMAXIS PTY LTD (AU) | 2004-04-14 | — | — | EP | disclosed |
| US-20030176363-A1 | Novel compounds and methods | PHARMAXIS PTY LTD. (AU) | 2003-09-18 | — | — | US | disclosed |
| EP-1301522-A1 | NOVEL COMPOUNDS AND METHODS | Pharmaxis Pty Ltd (AU) | 2003-04-16 | — | — | EP | disclosed |
| WO-2002004472-A1 | NOVEL COMPOUNDS AND METHODS | PHARMAXIS PTY LTD (AU) | 2002-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220098228-A1 | METHODS AND COMPOSITIONS FOR IMPROVING THE IMMUNE SYSTEM AND PROVIDING IMMUNO-PROTECTION | UTS2R, DHCR7, CYP8B1 | PYGB 709/4885PYGL 549/4885PYGM 1872/4885 |
| US-20030176363-A1 | Novel compounds and methods | NFATC1, CD4, CCR5 | PYGB 1649/4885PYGL 409/4885PYGM 592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.